Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TECH Stock Forecast 2026-2027
$51.99
Current Price
$8.14B
Market Cap
Buy 11
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to TECH Price Targets
+44.3%
To High Target of $75.00
+19.3%
To Median Target of $62.00
-5.8%
To Low Target of $49.00
TECH Price Momentum
+0.6%
1 Week Change
+2.1%
1 Month Change
+6.8%
1 Year Change
-11.6%
Year-to-Date Change
-28.0%
From 52W High of $72.16
+20.3%
From 52W Low of $43.20
📊 TOP ANALYST CALLS
Did TECH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bio-Techne is one of their latest high-conviction picks.
Latest TECH Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, TECH has a bullish consensus with a median price target of $62.00 (ranging from $49.00 to $75.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $51.99, the median forecast implies a 19.3% upside. This outlook is supported by 11 Buy, 4 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TECH Analyst Ratings
11
Buy
4
Hold
0
Sell
TECH Price Target Range
Low
$49.00
Average
$62.00
High
$75.00
Current: $51.99
Latest TECH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TECH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2026 | RBC Capital | Dan Leonard | Outperform | Reinstates | $62.00 |
| May 7, 2026 | Citigroup | Buy | Maintains | $N/A | |
| May 7, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 7, 2026 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| Apr 6, 2026 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| Feb 6, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 5, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Feb 5, 2026 | Stifel | Hold | Maintains | $N/A | |
| Feb 5, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Feb 5, 2026 | UBS | Buy | Maintains | $N/A | |
| Feb 5, 2026 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| Jan 5, 2026 | Evercore ISI Group | In-Line | Downgrade | $N/A | |
| Nov 20, 2025 | Argus Research | Buy | Maintains | $N/A | |
| Nov 6, 2025 | UBS | Buy | Maintains | $N/A | |
| Nov 6, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Oct 14, 2025 | TD Cowen | Buy | Maintains | $N/A | |
| Oct 7, 2025 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Sep 3, 2025 | RBC Capital | Outperform | Upgrade | $N/A | |
| Aug 21, 2025 | Citigroup | Buy | Upgrade | $N/A | |
| Aug 7, 2025 | RBC Capital | Sector Perform | Maintains | $N/A |
Bio-Techne Corporation (TECH) Competitors
The following stocks are similar to Bio-Techne based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bio-Techne Corporation (TECH) Financial Data
Bio-Techne Corporation has a market capitalization of $8.14B with a P/E ratio of 76.0x. The company generates $1.21B in trailing twelve-month revenue with a 9.0% profit margin.
Revenue growth is -1.5% quarter-over-quarter, while maintaining an operating margin of +25.2% and return on equity of +5.3%.
Valuation Metrics
Market Cap
$8.14B
Enterprise Value
$8.40B
P/E Ratio
76.0x
PEG Ratio
0.6x
Price/Sales
6.9x
Growth & Margins
Revenue Growth (YoY)
-1.5%
Gross Margin
+66.9%
Operating Margin
+25.2%
Net Margin
+9.0%
EPS Growth
+126.0%
Financial Health
Cash/Price Ratio
+2.6%
Current Ratio
4.5x
Debt/Equity
13.9x
ROE
+5.3%
ROA
+7.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bio-Techne Corporation (TECH) Business Model
About Bio-Techne Corporation
What They Do
Develops tools for life sciences research and diagnostics.
Business Model
The company generates revenue by developing, manufacturing, and supplying specialized reagents, analytical instruments, and diagnostic products to various sectors, including pharmaceuticals, biotechnology, and clinical laboratories. Bio-Techne's diverse offerings, including antibodies and advanced diagnostic solutions, cater to a wide range of customers engaged in drug discovery and clinical research.
Additional Information
Incorporated in 1981 and based in Minneapolis, Minnesota, Bio-Techne has established itself as a significant player in the global life sciences market. The company is committed to ensuring high-quality results in laboratory workflows, thus supporting advancements in both research and clinical diagnostics.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
3,100
CEO
Mr. Kim Kelderman
Country
United States
IPO Year
1992
Website
www.bio-techne.comBio-Techne Corporation (TECH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 05, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Techne (TECH) reported earnings 30 days ago; investors should monitor upcoming developments and potential market reactions for future stock performance.
Why It Matters
Techne's recent earnings report signals its financial health and growth potential, influencing investor sentiment and stock performance. Future projections could impact stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
3 days ago
Quick Summary
Bio-Techne and Refeyn have launched a new integrated workflow for characterizing charge and size variants in bispecific antibodies, enhancing biosimilar manufacturing efficiency.
Why It Matters
The new integrated workflow enhances efficiency and accuracy in biosimilar manufacturing, reducing development risks and potentially increasing Bio-Techne's market competitiveness and revenue.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
SpaceX's Starlink broadband service is expanding rapidly, creating significant value. CoStar Group shares dropped due to concerns over AI's potential negative impact on its business.
Why It Matters
SpaceX's Starlink growth indicates strong market potential, while CoStar's share decline reflects investor concerns over AI's disruption, impacting valuations and sector sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Bio-Techne Corporation (TECH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
25 days ago
Quick Summary
Bio-Techne Corporation (TECH) presented at the Bank of America Global Healthcare Conference 2026, providing insights into their operations and future plans.
Why It Matters
Bio-Techne's presentation may signal growth prospects and strategic direction, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Bio-Techne reported third-quarter revenue below Wall Street estimates, citing reduced U.S. academic funding as a factor impacting demand for its drug-development products.
Why It Matters
Bio-Techne's missed revenue estimates indicate weakened demand due to academic funding cuts, signaling potential challenges for growth and profitability in the biotech sector.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Bio-Techne Corporation (TECH) held its Q3 2026 earnings call, discussing financial results and company performance. Further details on revenue and growth strategies were shared.
Why It Matters
Bio-Techne's Q3 earnings report provides insights into its financial health and growth prospects, influencing stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About TECH Stock
What is Bio-Techne Corporation's (TECH) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Bio-Techne Corporation (TECH) has a median price target of $62.00. The highest price target is $75.00 and the lowest is $49.00.
Is TECH stock a good investment in 2026?
According to current analyst ratings, TECH has 11 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $51.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TECH stock?
Wall Street analysts predict TECH stock could reach $62.00 in the next 12 months. This represents a 19.3% increase from the current price of $51.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bio-Techne Corporation's business model?
The company generates revenue by developing, manufacturing, and supplying specialized reagents, analytical instruments, and diagnostic products to various sectors, including pharmaceuticals, biotechnology, and clinical laboratories. Bio-Techne's diverse offerings, including antibodies and advanced diagnostic solutions, cater to a wide range of customers engaged in drug discovery and clinical research.
What is the highest forecasted price for TECH Bio-Techne Corporation?
The highest price target for TECH is $75.00 from at , which represents a 44.3% increase from the current price of $51.99.
What is the lowest forecasted price for TECH Bio-Techne Corporation?
The lowest price target for TECH is $49.00 from at , which represents a -5.8% decrease from the current price of $51.99.
What is the overall TECH consensus from analysts for Bio-Techne Corporation?
The overall analyst consensus for TECH is bullish. Out of 2 Wall Street analysts, 11 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $62.00.
How accurate are TECH stock price projections?
Stock price projections, including those for Bio-Techne Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 1:58 PM UTC